Likewise, available data from 542 and 1080 patients with and without psychiatric disorders, respectively, showed a trend at post‐treatment week 12 towards slightly decreased fatigue scores as assessed by the FSS in patients with and without psychiatric disorders (−0.5 ± 1.6 and −0.3 ± 1.6, respectively). 4 DISCUSSION The pangenotypic, once‐daily DAA regimen of G/P achieved high (>97%) SVR12 rates in both patients with and without a psychiatric disorder.
← all excerpts
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
1
—
—